JP2014098034A5 - - Google Patents

Download PDF

Info

Publication number
JP2014098034A5
JP2014098034A5 JP2014034861A JP2014034861A JP2014098034A5 JP 2014098034 A5 JP2014098034 A5 JP 2014098034A5 JP 2014034861 A JP2014034861 A JP 2014034861A JP 2014034861 A JP2014034861 A JP 2014034861A JP 2014098034 A5 JP2014098034 A5 JP 2014098034A5
Authority
JP
Japan
Prior art keywords
hydroxyvitamin
concentration
serum
pharmaceutical composition
dihydroxyvitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014034861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014098034A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014098034A publication Critical patent/JP2014098034A/ja
Publication of JP2014098034A5 publication Critical patent/JP2014098034A5/ja
Pending legal-status Critical Current

Links

JP2014034861A 2007-04-25 2014-02-26 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法 Pending JP2014098034A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91385007P 2007-04-25 2007-04-25
US60/913,850 2007-04-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010506524A Division JP2010525080A (ja) 2007-04-25 2008-04-25 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017017323A Division JP2017075183A (ja) 2007-04-25 2017-02-02 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法

Publications (2)

Publication Number Publication Date
JP2014098034A JP2014098034A (ja) 2014-05-29
JP2014098034A5 true JP2014098034A5 (OSRAM) 2014-07-24

Family

ID=39926088

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010506524A Pending JP2010525080A (ja) 2007-04-25 2008-04-25 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法
JP2014034861A Pending JP2014098034A (ja) 2007-04-25 2014-02-26 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法
JP2017017323A Pending JP2017075183A (ja) 2007-04-25 2017-02-02 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法
JP2017205043A Pending JP2018009040A (ja) 2007-04-25 2017-10-24 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法
JP2019144447A Pending JP2019196402A (ja) 2007-04-25 2019-08-06 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010506524A Pending JP2010525080A (ja) 2007-04-25 2008-04-25 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017017323A Pending JP2017075183A (ja) 2007-04-25 2017-02-02 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法
JP2017205043A Pending JP2018009040A (ja) 2007-04-25 2017-10-24 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法
JP2019144447A Pending JP2019196402A (ja) 2007-04-25 2019-08-06 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法

Country Status (10)

Country Link
US (3) US20100144684A1 (OSRAM)
EP (3) EP3225243B1 (OSRAM)
JP (5) JP2010525080A (OSRAM)
CA (1) CA2683514C (OSRAM)
DK (2) DK3335712T3 (OSRAM)
ES (2) ES3044311T3 (OSRAM)
FI (2) FI3335712T3 (OSRAM)
PT (2) PT3335712T (OSRAM)
SI (1) SI3225243T1 (OSRAM)
WO (1) WO2008134523A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
EP1993559B1 (en) 2006-02-03 2016-06-22 OPKO Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
JP2010525080A (ja) 2007-04-25 2010-07-22 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
CA2684778C (en) 2007-04-25 2017-09-05 Cytochroma Inc. Methods and compounds for vitamin d therapy
HRP20231142T3 (hr) 2007-04-25 2024-01-05 Eirgen Pharma Ltd. Kontrolirano oslobađanje 25-hidroksivitamina d
AU2009214049B2 (en) * 2008-02-13 2014-02-06 Dsm Ip Assets B.V. Combination of vitamin D and 25-hydroxyvitamin D 3
ES2954932T3 (es) 2008-04-02 2023-11-27 Eirgen Pharma Ltd Métodos, composiciones, usos y kits útiles para la deficiencia de vitamina D y trastornos relacionados
US20110034426A1 (en) * 2009-08-03 2011-02-10 Wisconsin Alumni Research Foundation Method of Preventing Renal Disease and Treating Symptoms Thereof
US8518917B2 (en) * 2009-10-02 2013-08-27 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin D analogs and their uses
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
ES2712740T3 (es) * 2010-12-06 2019-05-14 Dsm Ip Assets Bv Tratamiento de afecciones asociadas con eotaxina incrementada con 25-hidroxivitamina D3
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CN114681468A (zh) * 2014-08-07 2022-07-01 欧普科爱尔兰环球控股有限公司 利用25-羟基维生素d的辅助疗法
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
WO2017117712A1 (zh) * 2016-01-05 2017-07-13 富士通株式会社 信息传输方法、装置和系统
CN108883120A (zh) 2016-03-28 2018-11-23 欧普科爱尔兰环球控股有限公司 维生素d治疗方法
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
KR20200140284A (ko) 2018-04-03 2020-12-15 옵코 아일랜드 글로벌 홀딩스 리미티드 비만대사 수술 환자에서의 칼시페디올의 용도
JP2022519789A (ja) 2019-02-06 2022-03-24 エアジェン ファーマ リミテッド カルシフェジオールを用いた副甲状腺機能亢進症の進行を制御する方法、およびそれに使用するための組成物
AU2021285494A1 (en) * 2020-05-31 2022-12-08 Eirgen Pharma Ltd. Hard capsule dosage form and uses thereof
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565924A (en) 1968-07-01 1971-02-23 Wisconsin Alumni Res Found 25-hydroxycholfcalciferol
US3833622A (en) 1969-03-17 1974-09-03 Upjohn Co Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds
US3974272A (en) * 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US3880894A (en) 1974-05-24 1975-04-29 Wisconsin Alumni Res Found 1,25-Dihydroxyergocalciferol
US4004003A (en) 1974-08-28 1977-01-18 The Upjohn Company 25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis
US4335120A (en) 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4230701A (en) 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
JPS5832823A (ja) 1981-08-20 1983-02-25 Chugai Pharmaceut Co Ltd 脱癌剤
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
JPS59155309A (ja) 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
US4684524A (en) 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4555364A (en) 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
US4695591A (en) 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4668517A (en) 1985-04-04 1987-05-26 Norwich Eaton Pharmaceuticals, Inc. Furazolidone dosage form
DE3676235D1 (de) 1985-06-04 1991-01-31 Teijin Ltd Arzneizubereitung mit verzoegerter wirkstoffabgabe.
JPS61293911A (ja) 1985-06-24 1986-12-24 Teisan Seiyaku Kk 徐放化製剤
US5167965A (en) * 1987-02-09 1992-12-01 The Dow Chemical Company Palatable cholestyramine granules, tablets and methods for preparation thereof
US4997824A (en) 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5104864A (en) 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
JP2893191B2 (ja) 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
JPH02240024A (ja) 1989-03-13 1990-09-25 Ss Pharmaceut Co Ltd 活性型ビタミンｄ↓３類製剤用組成物
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
GB9004544D0 (en) 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
JP2845342B2 (ja) 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
JP2893140B2 (ja) 1990-11-30 1999-05-17 エスエス製薬株式会社 安定なビタミンｄ製剤
JPH04288016A (ja) 1991-03-14 1992-10-13 Tokai Capsule Kk 活性型ビタミンｄ３類軟カプセル剤の製造方法
NZ242271A (en) 1991-04-09 1993-10-26 Takeda Chemical Industries Ltd Medicaments containing a vitamin d compound stabilised by a basic substance
US5693615A (en) 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5160742A (en) 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5795882A (en) 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
DK0600079T3 (da) 1992-06-22 2002-04-15 Bone Care Int Inc Oral 1alpha-hydroxyprævitamin D
US5354743A (en) * 1992-09-15 1994-10-11 Thys Jacobs Susan Method for the treatment of premenstrual syndrome with vitamin D
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5342626A (en) 1993-04-27 1994-08-30 Merck & Co., Inc. Composition and process for gelatin-free soft capsules
JP2684587B2 (ja) 1993-06-21 1997-12-03 呉羽化学工業株式会社 腎性骨異栄養症における骨量減少抑制剤
US6121469A (en) 1993-12-23 2000-09-19 The Regents Of The University Of California Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs
JPH07242550A (ja) * 1994-03-02 1995-09-19 Teijin Ltd 二次性副甲状腺機能亢進症治療剤
IL110117A0 (en) 1994-06-24 1994-10-07 Univ Ben Gurion Pharmaceutical compositions comprising vitamin-d analogs
SE9402422D0 (sv) 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
JPH10504291A (ja) 1994-07-22 1998-04-28 ジー．ディー．サール アンド カンパニー 自己乳化性ドラッグデリバリーシステム
JPH0892098A (ja) 1994-09-27 1996-04-09 Teijin Ltd 肺結核治療剤
US5756123A (en) 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US6376479B1 (en) 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
JP3372259B2 (ja) 1995-09-21 2003-01-27 ウィスコンシン・アルムニ・リサーチ・ファウンデーション カルシトリオール誘導体およびそれらの用途
DE19549243A1 (de) 1995-12-21 1997-06-26 Schering Ag Pharmazeutische Präparate enthaltend Clathrate von Cyclodextrinen und nichtnatürliche Vitamin D-Analoga
EP0949927B1 (en) * 1996-08-26 2002-10-16 Takeda Chemical Industries, Ltd. Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
US5958451A (en) 1996-09-03 1999-09-28 Yung Shin Pharm Ind. Co., Ltd. Process for producing porous, controlled-release capsules and encapsulated composition
DE69730982T2 (de) 1996-10-28 2005-09-01 General Mills, Inc., Minneapolis Einbettung und einkapselung von teilchen zur kontrollierten abgabe
JPH10158171A (ja) 1996-12-02 1998-06-16 Kita:Kk ビタミンｄ化合物を配合した眼内投与剤
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US20030129194A1 (en) 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US6034075A (en) 1997-03-20 2000-03-07 The Trustees Of Columbia University In The City Of New York Method of treating polycystic ovarian syndrome
JPH1175863A (ja) 1997-07-10 1999-03-23 Kyowa Hakko Kogyo Co Ltd ２５−ヒドロキシビタミンＤ３−１α−水酸化酵素および該酵素をコードするＤＮＡ
WO1999011272A1 (en) 1997-09-02 1999-03-11 Johns Hopkins University School Of Medicine Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
EP2340840B1 (en) 1998-03-27 2012-08-29 Oregon Health Sciences University Pulse dose Vitamin D drug for the treatment of hyperproliferative skin diseases
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
ATE487471T1 (de) 1998-08-27 2010-11-15 Pfizer Health Ab Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
US6139875A (en) 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
EP2266542A3 (en) 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
EP1119345B1 (en) 1998-10-09 2009-04-29 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
JP3449253B2 (ja) 1998-10-29 2003-09-22 シオノギクオリカプス株式会社 硬質カプセルの製造方法
JP2000206312A (ja) * 1998-11-12 2000-07-28 Olympus Optical Co Ltd 光学素子
CN1161101C (zh) 1998-12-17 2004-08-11 阿尔扎有限公司 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6432936B1 (en) 1999-01-20 2002-08-13 Wisconsin Alumni Research Foundation Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1180035B1 (en) 1999-04-01 2006-11-02 Johns Hopkins University NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1-alpha, 25-DIHYDROXY VITAMIN D3
DE19916419B4 (de) 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
WO2000072831A1 (en) * 1999-05-27 2000-12-07 Drugtech Corporation Nutritional formulations
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6893658B1 (en) 1999-08-31 2005-05-17 Chugai Seiyaku Kabushiki Kaisha Soft capsules
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0007419D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
US6375981B1 (en) 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
IL153378A0 (en) * 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
BR0113570A (pt) 2000-08-29 2004-07-06 Nisshin Kasei Co Ltd Cápsula rìgida
BR0115382A (pt) 2000-10-30 2003-09-16 Euro Celtique Sa Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica
US6479649B1 (en) 2000-12-13 2002-11-12 Fmc Corporation Production of carrageenan and carrageenan products
BR0209644A (pt) * 2001-05-15 2004-07-06 Warner Lambert Co Processo de compactação para fabricação de uma forma de dosagem de fenitoìna de sódio
CN100366239C (zh) 2001-07-05 2008-02-06 涌永制药株式会社 软胶囊剂
US7033996B2 (en) 2001-08-31 2006-04-25 University Of Medicine & Dentistry Of New Jersey Method for the treatment of vitamin D related disease
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
ES2283593T3 (es) 2001-10-12 2007-11-01 Johns Hopkins University Analogos de oxima poco calcemicos de 1alfa,25-dihidroxi vitamina d3.
US6524788B1 (en) 2001-11-02 2003-02-25 Thomas L. Cantor Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
US7056655B2 (en) 2001-11-02 2006-06-06 Scantibodies Laboratory, Inc. Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
EP1447082B1 (en) 2001-11-22 2010-11-10 Morishita Jintan Co., Ltd. Non-gelatinous capsules
JP2005515996A (ja) 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンｄ化合物を含む薬学的組成物
FR2829142B1 (fr) 2001-12-27 2004-02-13 Ulice Composition filmogene d'heteroxylanes pour la fabrication de capsules ainsi obtenues
US7632518B2 (en) 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
NO20021592D0 (no) 2002-04-04 2002-04-04 Fmc Biopolymer As Polysakkaridkapsler og fremgangsmåte ved fremstilling derav
JP2005531532A (ja) * 2002-04-05 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法
ATE543796T1 (de) 2002-06-13 2012-02-15 Univ Johns Hopkins 24-sulfoximine vitamin d3 derivate
US20060127484A1 (en) 2002-07-05 2006-06-15 Speirs Christopher J Controlled release composition
JP4500679B2 (ja) * 2002-07-29 2010-07-14 アルザ・コーポレーシヨン パリペリドンを制御送達する方法および投薬形態物
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
WO2004028515A1 (en) 2002-09-26 2004-04-08 Young-Kweon Choi Matrix type patch for transdermal administration of vitamin d analog and the use thereof
US20050101576A1 (en) 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US8999372B2 (en) 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
JP2004175750A (ja) 2002-11-28 2004-06-24 Kose Corp 皮膚障害抑制剤、皮膚障害改善剤、及びそれらを含有する皮膚外用剤
GB2411116B (en) 2002-12-16 2009-04-29 Teva Pharma Increasing the bioavailability of alendronate by predose administration of alphacalcidol
EP1592410B1 (en) * 2003-02-11 2008-07-23 Alza Corporation Methods and dosage forms with modified layer geometry
JP2006526057A (ja) 2003-04-14 2006-11-16 エフ　エム　シー　コーポレーション 均一で熱可逆性の低粘度ポリマンナンガムフィルム及びそれからつくったソフトカプセル
US7816341B2 (en) 2003-04-14 2010-10-19 Fmc Corporation Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
JP2006525367A (ja) * 2003-04-30 2006-11-09 ビオクセル エッセ ピ ア ジェミニビタミンｄ３化合物及びその使用方法
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
JP2007526013A (ja) 2003-06-16 2007-09-13 ソルクス インコーポレイテッド 緑内障を治療するためのシャント装置
US20050148557A1 (en) 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
EP1663249A4 (en) * 2003-09-24 2006-12-20 Bioxell Spa 1,3-DIACYLATED, 26,27-ALKYL / HALOALKYL VITAMIN D SB 3 / SB COMPOUNDS AND APPLICATION METHOD THEREFOR
US7053075B2 (en) 2003-11-25 2006-05-30 Deluca Hector F Methods for reducing body fat using vitamin D compounds
US20060009425A1 (en) 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
JP2008502605A (ja) 2004-06-16 2008-01-31 スマート ドラッグ システムズ インコーポレイティド 徐放性ワクチン組成物
WO2006007323A2 (en) 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
US20060019933A1 (en) 2004-07-22 2006-01-26 David Boardman Process for preparing stabilized vitamin D
EP1781262A1 (en) 2004-07-29 2007-05-09 Sanofi-Aventis Pharmaceutical multilayer tablet for controlled_release of active ingredients with highly ph-dependent solubility
WO2006044657A2 (en) * 2004-10-15 2006-04-27 Altairnano, Inc. Phosphate binder with reduced pill burden
US8231896B2 (en) 2004-11-08 2012-07-31 R.P. Scherer Technologies, Llc Non-gelatin soft capsule system
AU2004325362B2 (en) 2004-12-03 2012-09-06 Council Of Scientific And Industrial Research Process of preparation of biodegradable films from semi refined kappa carrageenan
US8318210B2 (en) 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
US7745226B2 (en) 2005-04-06 2010-06-29 Quest Diagnostics Investments Incorporated Methods for detecting vitamin D metabolites
ES2930658T3 (es) 2005-04-15 2022-12-20 Tolmar Inc Sistemas de administración farmacéutica para medicamentos hidrofóbicos y composiciones que comprenden los mismos
US20060257481A1 (en) 2005-04-21 2006-11-16 Decode Genetics Ehf. Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
US20080134937A1 (en) 2005-05-25 2008-06-12 Joo Hwan Yang Cellulose hard capsule enhancing mechanical film strength
AR055099A1 (es) 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
CA2624124A1 (en) 2005-09-29 2007-04-12 F. Hoffmann-La Roche Ag Antibodies against 25-hydroxyvitamin d
ITFI20050206A1 (it) 2005-09-30 2007-04-01 Valpharma Sa Composizione farmaceutica a rilascio controllato di venlafaxina cloridrato, e processo per la sua preparazione
CA2624897C (en) * 2005-10-12 2017-02-14 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
JP5406529B2 (ja) 2005-10-26 2014-02-05 バナー ファーマキャプス， インコーポレイテッド カプセル充墳物としての親油性ベヒクルに基づく二重制御された放出マトリクスシステム
CA2627292C (en) 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
EA015170B1 (ru) 2005-11-01 2011-06-30 СиПи КЕЛКО Ю.С., ИНК. Высоковязкие диутановые камеди и способы их получения
WO2007068287A1 (en) 2005-12-15 2007-06-21 Laboratoria Qualiphar Sustained release vitamin preparation
EP1993559B1 (en) * 2006-02-03 2016-06-22 OPKO Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
EP2024436A1 (en) 2006-06-06 2009-02-18 Fmc Corporation Kappa-2 carrageenan composition and products made therefrom
ES2670029T3 (es) * 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
WO2008050209A1 (en) 2006-10-27 2008-05-02 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
US8501717B2 (en) 2007-02-09 2013-08-06 Merck, Sharp & Dohme Corp. Methods to treat and/or prevent mucositis
JP2010525080A (ja) 2007-04-25 2010-07-22 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法
HRP20231142T3 (hr) 2007-04-25 2024-01-05 Eirgen Pharma Ltd. Kontrolirano oslobađanje 25-hidroksivitamina d
CA2683628C (en) 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
DE102008006203B4 (de) * 2008-01-26 2011-03-17 Jost-Werke Gmbh Fahrzeugkupplung zum Herstellen einer mechanischen Verbindung zwischen einem ersten und einem zweiten Fahrzeug
WO2009101137A1 (en) 2008-02-13 2009-08-20 Dsm Ip Assets B.V. Use of 25-hydroxy-vitamin d3 to affect human muscle physiology
AU2009214049B2 (en) 2008-02-13 2014-02-06 Dsm Ip Assets B.V. Combination of vitamin D and 25-hydroxyvitamin D 3
US8759328B2 (en) 2008-07-24 2014-06-24 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration
SI2341899T1 (sl) 2008-09-24 2015-04-30 Evonik Roehm Gmbh Od pH odvisen opioidni farmacevtski sestavek z nadzorovanim sproščanjem z odpornostjo na vpliv etanola
TR201904204T4 (tr) 2009-09-10 2019-04-22 Dupont Nutrition Usa Inc Eklemsiz aljinat kapsülleri.
US8101203B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
US8101204B2 (en) 2010-01-14 2012-01-24 Karl Wei Cao Hard capsule composition and method of use
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
MX344742B (es) 2010-08-04 2017-01-05 Scherer Technologies Llc R P Composicion de formacion de pelicula para capsulas suaves.
ES2712740T3 (es) 2010-12-06 2019-05-14 Dsm Ip Assets Bv Tratamiento de afecciones asociadas con eotaxina incrementada con 25-hidroxivitamina D3
RU2579312C2 (ru) 2010-12-28 2016-04-10 Футуре Диагностикс Б.В. Реагент для высвобождения витамина d
DK2680826T3 (en) 2011-03-02 2017-10-09 D3 Pharma Ltd VITAMIN D COMPOSITION
ES2617654T3 (es) 2011-04-20 2017-06-19 Suheung Co., Ltd. Composición de la cubierta de cápsula blanda de origen no animal que tiene dureza de la cubierta y desintegración, mejoradas
CN102771688A (zh) 2011-05-13 2012-11-14 富曼实（上海）商贸有限公司 可食用液体填充的多糖胶囊
EP2815745A1 (en) 2013-06-21 2014-12-24 Swiss Caps Rechte und Lizenzen AG Soft shell capsule and process for its manufacture
CN103495176B (zh) 2013-10-26 2015-01-28 中山市凯博思淀粉材料科技有限公司 一种共混挤出法制备淀粉基软胶囊的方法
CN103520133B (zh) 2013-10-26 2015-02-04 中山市凯博思淀粉材料科技有限公司 一种淀粉基软胶囊的制备方法

Similar Documents

Publication Publication Date Title
JP2014098034A5 (OSRAM)
JP2010525080A5 (OSRAM)
JP2017075183A5 (OSRAM)
Malberti Hyperphosphataemia: treatment options
FI3225243T3 (fi) Menetelmä sekundaarisen hyperparatyreoosin turvalliseen ja tehokkaaseen hoitoon ja ehkäisyyn kroonisen munuaistaudin yhteydessä
Heim et al. Vitamin D (25-OHD) deficiency may increase the prevalence of medication-related osteonecrosis of the jaw
WO2008008608A3 (en) Method of treating and preventing secondary hyperparathyroidism
MX2020011737A (es) Metodos de tratamiento con vitamina d.
JP2017002086A5 (OSRAM)
Haghverdi et al. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5
Akram et al. Clinical characteristics and therapeutic management of osteogenesis imperfecta in Iraqi children
MX2022013681A (es) Metodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis.
Shahidi et al. Low-dose pamidronate for treatment of early bone loss following kidney transplantation: a randomized controlled trial
Shahnazari et al. Secondary hyperparathyroidism in chronic kidney failure
Alshayeb et al. Treatment Of Chronic Kidney Disease Mineral Bone Disorder (CKD‐MBD)
El-Reshaid et al. The beneficial effect of paricalcitol (Zemplar) on secondary hyperparathyroidism refractory to calcitriol (Calcijex) and cinacalcet HCl (Mimpara) in patients on maintenance hemodialysis: a prospective and crossover study
Kadhem Blood calcium balance and dialysate calcium concentration in heamodialysis patients in Thi-Qar Province, Iraq
Spasovski New aspects of treatment of renal bone disease in dialysis patients
Molony Recognition and Management of Mineral and Bone Disorder of Chronic Kidney Disease and End‐Stage Renal Disease
Mazoni et al. SAT-391 Safety and Efficacy of Conventional Therapy with Calcium and Activated Vitamin D in Patients with Chronic Post-Operative Hypoparathyroidism: Results of a Cross-Sectional Case-Control Study
WO2025094144A1 (en) Controlling loss of kidney function
Baek Abdominal aortic aneurysm rupture (first report) following intravitreal administration in an elderly patient: case report
Rosa Primary hypoparathyroidism and symptoms of major depression secondary to hypomagnesaemia: case report
Kapoor Various toxicities: case report
Veighey et al. Renal bone disease